|
|
|
|
|
|
|
|
Join this Clinical Leader Live on 9-22-26 to explore smarter ways to evaluate site capabilities, patient availability, recruitment potential, protocol burden, and virtual versus in-person trial activities. Discover how sponsors can move beyond feasibility paperwork to make better decisions about whether, where, and how a clinical trial can succeed. Register today to join the discussion.
|
|
|
|
|
|
|
|
|
|
Four Trends In Obesity Clinical Trials
|
|
Article | Flourish Research
|
Retention, body composition, maintenance therapy, amylin combinations, and behavioral support are reshaping obesity trials. Learn how sponsors can reduce dropout risk and strengthen clinical data.
|
|
|
|
|
|
How AI Can Accelerate Clinical Trial And Registry Builds
|
|
Video | Crucial Data Solutions
|
AI tools speed study design — from protocol creation to validation and analysis — by automating complex tasks and generating intelligent data while preserving control, accuracy, and flexibility.
|
|
|
|
|
|
5 Questions To Ask Before Selecting A Randomization Partner
|
|
White Paper | By Jennifer Ross, Almac Clinical Technologies
|
Choose the right IRT partner for complex master protocols. Learn how adaptive randomisation expertise and flexible technology reduce disruption and keep trials execution-ready.
|
|
|
|
|
|
|
|
Transforming European Case Intake Operations
|
|
Case Study | By PrimeVigilance, Ergomed Group
|
Centralized intake and semi‑automation brought clarity and control to European safety reporting, improving oversight, data quality, and compliance across multiple partners and countries.
|
|
|
|
|
|
|
|
|
|
Webinar: Scaling Pharmacovigilance: From Clinical Development to Commercialization
|
Pharmacovigilance becomes more complex as biopharma companies move toward commercialization and global growth. In this webinar, Nina Lahanis draws on 30+ years of pharmaceutical experience and 16+ years in PV leadership to share practical lessons on building scalable operating models, preparing for commercial readiness, navigating technology and governance decisions, and strengthening resilience in an evolving regulatory environment. Register for actionable insights. Click here to learn more.
|
|
|
|
|
|
|
|
DCT Benefits Are Proven, Yet Progress Is Slow
|
|
From The Editor | By Dan Schell, Chief Editor, Clinical Leader
|
Despite the clear benefits of decentralized trials—broader reach, better retention, and higher diversity—adoption has been slow. In this interview, Sunny Kumar of Informed Ventures explains how AI is lowering costs, speeding up study builds, and pushing DCTs from fringe to future.
|
|
|
|
|
| Connect With Clinical Leader: |
|
|
|
|
